by Madaline Spencer | Aug 14, 2024
Maria Fleseriu, MD, Director of the Pituitary Center at Oregon Health and Science University, discusses a post hoc analysis of three phase 3 studies analyzing the use of oral octreotide in patients with acromegaly. Acromegaly is a hormonal disorder that...
by Madaline Spencer | Aug 13, 2024
James “Brad” Elder, MD, Director of Neurosurgical Oncology at the Ohio State University Comprehensive Cancer Center, discusses a clinical trial evaluating the investigational gene therapy, AVB-101 in patients with frontotemporal dementia (FTD). FTD is a...
by Madaline Spencer | Aug 12, 2024
Kelly Knupp, MD, Associate Professor of Pediatrics and Neurology at the University of Colorado, discusses supplemental data on the efficacy of fenfluramine in treating Dravet syndrome-associated seizures. Dravet syndrome is the most severe of a group of...
by Madaline Spencer | Aug 8, 2024
Pisit “Duke” Pitukcheewanont, MD, Chief Medical Officer for Lumos Pharma, discusses a phase 2 trial evaluating LUM-201 (ibutamoren) for treatment of growth hormone deficiency. Pediatric growth hormone deficiency (PGHD) is a rare condition characterized...
by Madaline Spencer | Aug 7, 2024
Jula Inrig, MD, Chief Medical Officer at Travere Therapeutics, discusses a clinical trial that tested sparsentan for treatment of IgA nephropathy, compared to traditional RAS inhibitors. IgA nephropathy (IgAN) is a rare kidney disorder that occurs when...
